The Global Cell-free DNA (cfDNA) testing market is anticipated to grow at a CAGR of 18.52% in terms of a number of units and 16.46% in terms of revenue between 2018 and 2026. Cell-free DNA testing has been a new technology in which free-flowing DNA fragments, from a small quantity of liquid sample (saliva, urine, or blood) from patients, are analyzed. The Cell-free DNA (cfDNA) testing market is primarily driven by the following factors:
GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET FORECAST 2018-2026
Global Cell-free Dna (Cfdna) Testing Market by Products (Automated Instruments, Consumables, Extraction/isolation Kits) by Platform (Ngs, Rpcr and Multiplexed, Pcr, Qpcr, Dpcr, Other Platform) by Application (Oncology, Nipt, Other Disease Conditions) by Geography.
The Global Cell-free DNA (cfDNA) testing market is anticipated to grow at a CAGR of 18.52% in terms of a number of units and 16.46% in terms of revenue between 2018 and 2026. Cell-free DNA testing has been a new technology in which free-flowing DNA fragments, from a small quantity of liquid sample (saliva, urine, or blood) from patients, are analyzed. The Cell-free DNA (cfDNA) testing market is primarily driven by the following factors:
- Increasing the risk of chronic diseases due to unhealthy lifestyle
- Advances in molecular pathogenesis
- Rising parasitic infection
- The surge in prenatal complication
- Awareness for prenatal testing
To know more about this report, request a free sample copy.
The important driver increasing growth in the global cell-free DNA (cfDNA) testing market is the increased risk of chronic diseases due to unhealthy lifestyle and advances in molecular pathogenesis. Unhealthy lifestyle increases the risk of chronic diseases that persists for a long time. Health damaging lifestyle behaviour such as the increased use of tobacco and alcohol, lack of physical activity, poor eating habits or heavy consumption of fast foods, are the major causative factors for chronic diseases. Advances in the molecular pathogenesis of cancer have promoted the study of early molecular alterations including genetic and epigenetic alterations involved in cancer developments in body fluids.
The cell-free DNA (cfDNA) testing market platforms and applications are used extensively for various purposes. The commercially available NIPT tests allow routine antenatal care and help in detecting chromosomal abnormalities. In RT-PCR (Reverse Transcription PCR), the preliminary genetic material in the PCR response is RNA, which is transcribed in reverse into DNA complement by the help of reverse transcriptase enzyme. Quantitative PCR (qPCR) is used to characterize, detect and enumerate nucleic acids for many applications. Digital polymerase chain reaction (dPCR) is a new method for quantifying and detecting a nucleic acid. Cell-free DNA is usually released by all types of cells and mainly originate from necrotic or apoptotic cells. Recent developments highlighted the discovery of massively parallel shotgun sequencing (MPSS), a kind of NGS technique that non-specifically generates different DNA sequence reads from a complete set of chromosomes. The cfDNA analysis is also applied to graft rejection, cardiovascular disorders, immunological diseases, trauma, and infection.
The high cost of treatment and shortage of skilled professionals are the major factors hindering the cell-free DNA (cfDNA) testing market. Analysis of cell-free DNA is usually an expensive process. The high cost of the test, along with the lack of strong reimbursement policies is a major restraint to the development of the cell-free DNA extraction/isolation market. In fact, the shortage of skilled professionals has been a major problem in the healthcare sector across the globe.
The Global Cell-free DNA (cfDNA) testing market segments include products, platforms, and applications.
Products are segmented into:
- Automated instruments
- Consumables
- Extraction/isolation kits
- Magnetic bead-based
- Column-based
- Other extraction/isolation kits
Platforms are segmented into:
- NGS
- rPCR and multiplexed PCR
- qPCR
- dPCR
- Other platform
Applications are segmented into:
- Oncology
- NIPT
- Other Disease Conditions
This report covers the present market conditions and the growth prospects of the global Cell-free DNA (cfDNA) testing market for 2018-2026 and considered the revenue generated through the sales of cell-free DNA (cfDNA) testing for products, platforms, and applications to calculate the market size by considering 2017 as the base year.
Geographically, the global cell-free DNA (cfDNA) testing market has been segmented on the basis of four major regions, which include:
- North America Cell-free Dna (Cfdna) Testing Market : The United States & Canada
- Asia-Pacific Cell-free Dna (Cfdna) Testing Market : China, India, Japan, Australia, South Korea & Rest of APAC
- EuropeCell-free Dna (Cfdna) Testing Market : The United Kingdom, France, Germany, Italy, Spain, Russia & Rest of Europe
- Rest of World: Latin America & Middle East and Africa
The Cell-free DNA (cfDNA) testing market in North America is expected to hold the largest share by 2026 owing to the growing demand for a non-invasive test for cancer screening. Diagnostic is the key driving factor for the growth of this market in the region. Moreover, the growing adoption of a non-invasive test for prenatal conditions has primarily increased the sales of cfDNA isolation products in the recent past. This is primarily due to the increasing demand for a non-invasive test for clinical and research studies. On the other hand, the Asia-Pacific market is anticipated to be the fastest-growing region for the Cell-free DNA (cfDNA) testing market. The Asia Pacific comprises of several countries that are witnessing significant growth in research and technological advances. The commercialization of cell-free DNA tests to detect chromosomal aneuploidies has been rapid, resulting in a steady market increase in the Asia-Pacific.
The Cell-free DNA (cfDNA) testing market is segmented based on products which are sub-divided into automated instruments, consumables & extraction/isolation kits. Extraction/Isolation Kits are further segmented into magnetic bead-based, column based and other extraction/isolation kits. Automated systems enable the isolation, amplification, and detection of cell-free DNA in a convenient way. Consumables refer to a wide range of elements ranging from pipettes to test-tubes that allow accurate and precise measurement during the analysis of cfDNA. Extraction/Isolation kits allow purification and enrichment of cfDNA by chemical means. Based on the method used, kits can further be divided into Magnetic-bead based kits and column based kits.
The major market players of the global Cell-free DNA (cfDNA) testing market are:
- Qiagen N.V.
- Nipd Genetics
- Merck Kgaa
- Illumina
- Thermo Fisher Scientific Inc
Company Profiles covers analysis of important players.
QIAGEN N.V. (Qiagen or ‘the company’) provides sample and assay technologies that are used to transform biological materials into valuable molecular information. Qiagen’s consumable products typically include sample technologies to extract and purify molecules of interest from biological samples and assay technologies that make the information in these genomic molecules available for analysis and interpretation. Thermo Fisher Scientific Inc. manufactures, develops, and provides analytical equipment, instruments, consumables and reagents software and services for research, analysis, discovery, manufacturing, and diagnostics.
Key Findings of the Global Cell-free DNA (cfDNA) testing market:
- Swelling sample numbers for screening and diagnostics using circulating cell-free DNA (cfDNA)
- Automated instruments are anticipated to grow significantly in terms of products
- Next-generation sequencing platform holds the largest market share
- NIPT is the majorly used application in the cfDNA testing market
- RESEARCH SCOPE
- STUDY GOALS
- SCOPE OF THE MARKET STUDY
- WHO WILL FIND THIS REPORT USEFUL?
- STUDY AND FORECASTING YEARS
- RESEARCH METHODOLOGY
- SOURCES OF DATA
- SECONDARY DATA
- PRIMARY DATA
- TOP DOWN APPROACH
- BOTTOM-UP APPROACH
- DATA TRIANGULATION
- SOURCES OF DATA
- EXECUTIVE SUMMARY
- MARKET SUMMARY
- KEY FINDINGS
- SWELLING SAMPLE NUMBERS FOR SCREENING AND DIAGNOSTICS USING CIRCULATING CELL-FREE DNA (CFFDNA)
- AUTOMATED INSTRUMENTS ARE ANTICIPATED TO GROW SIGNIFICANTLY IN TERMS OF PRODUCTS
- NEXT GENERATION SEQUENCING PLATFORM HOLDS THE LARGEST MARKET SHARE
- NIPT IS THE MAJORLY USED APPLICATION IN THE CFDNA TESTING MARKET
- MARKET DETERMINANTS
- MARKET DRIVERS
- INCREASING THE RISK OF CHRONIC DISEASES DUE TO UNHEALTHY LIFESTYLE
- ADVANCES IN MOLECULAR PATHOGENESIS
- RISING PARASITIC INFECTION
- SURGE IN PRENATAL COMPLICATION
- AWARENESS FOR PRENATAL TESTING
- MARKET RESTRAINTS
- HIGH COST OF TREATMENT
- SHORTAGE OF SKILLED PROFESSIONALS
- MARKET OPPORTUNITIES
- INCREASING COLLABORATIONS AND PARTNERSHIPS BETWEEN THE COMPANIES
- SCOPE FOR PERSONALIZED MEDICINES
- TECHNOLOGICAL ADVANCEMENT
- MARKET CHALLENGES
- REIMBURSEMENT ISSUES
- SOCIAL, LEGAL AND ETHICAL ISSUES
- MARKET DRIVERS
- MARKET SEGMENTATION
- MARKET BY PRODUCTS 2018-2026
- AUTOMATED INSTRUMENTS
- CONSUMABLES
- EXTRACTION/ISOLATION KITS
- MAGNETIC BEAD BASED
- COLUMN BASED
- OTHER EXTRACTION/ISOLATION KITS
- MARKET BY PLATFORM 2018-2026
- NGS
- RPCR AND MULTIPLEXED PCR
- QPCR
- DPCR
- OTHER PLATFORM
- MARKET BY APPLICATION 2018-2026
- ONCOLOGY
- NIPT
- OTHER DISEASE CONDITIONS
- MARKET BY PRODUCTS 2018-2026
- KEY ANALYTICAL
- PORTER’S FIVE FORCE MODEL
- THREAT OF NEW ENTRANTS
- THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
- BARGAINING POWER OF BUYER
- BARGAINING POWER OF SUPPLIER
- INTENSITY OF COMPETITIVE RIVALRY
- ETYMOLOGY OF CFDNA
- PRICING ANALYSIS
- BIOLOGICAL ROLE OF CFDNA
- APPLICATION OF CIRCULATING CELL-FREE DNA
- PORTER’S FIVE FORCE MODEL
- GEOGRAPHICAL ANALYSIS
- NORTH AMERICA
- THE UNITED STATES
- CANADA
- EUROPE
- THE UNITED KINGDOM
- GERMANY
- FRANCE
- ITALY
- SPAIN
- RUSSIA
- REST OF EUROPE
- ASIA PACIFIC
- CHINA
- JAPAN
- AUSTRALIA
- INDIA
- SOUTH KOREA
- REST OF ASIA PACIFIC
- REST OF WORLD
- LATIN AMERICA
- MIDDLE EAST AND AFRICA
- NORTH AMERICA
- COMPANY PROFILES
- COMPETITIVE LANDSCAPE
- MARKET SHARE ANALYSIS
- AGILENT TECHNOLOGIES INC.
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVE
- ACCUBIOMED
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- ALINE BIOSCIENCES
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- BERRY GENOMICS
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVE
- BIOO SCIENTIFIC CORPORATION
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- HOFFMANN-LA ROCHE LTD
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- GATC BIOTECH (ACQUIRED BY EUROFINS SCIENTIFIC)
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- ILLUMINA
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- LABORATORY CORPORATION OF AMERICA
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- MERCK KGAA
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- NATERA INC.
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- NIPD GENETICS
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- PREMAITHA HEALTH PLC
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- QIAGEN N.V.
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- THERMO FISHER SCIENTIFIC, INC.
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- COMPETITIVE LANDSCAPE
LIST OF TABLES
TABLE 1 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 2 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET BY GEOGRAPHY 2018-2026 (THOUSAND UNITS)
TABLE 3 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET BY PRODUCTS 2018-2026 ($ MILLION)
TABLE 4 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET BY PRODUCTS 2018-2026 (THOUSAND UNITS)
TABLE 5 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET IN EXTRACTION/ISOLATION KITS BY METHODS 2018-2026 ($ MILLION)
TABLE 6 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET IN EXTRACTION/ISOLATION KITS BY METHODS 2018-2026 (THOUSAND UNITS)
TABLE 7 COMMERCIALLY AVAILABLE ISOLATION KITS
TABLE 8 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET BY PLATFORM 2018-2026 ($ MILLION)
TABLE 9 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET BY PLATFORM 2018-2026 (THOUSAND UNITS)
TABLE 10 NEXT GENERATION SEQUENCING (NGS) AND POLYMERASE CHAIN REACTION (DPCR) COMPARISON
TABLE 11 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET BY APPLICATION 2018-2026 ($ MILLION)
TABLE 12 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET BY APPLICATION 2018-2026 (THOUSAND UNITS)
TABLE 13 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 14 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET BY GEOGRAPHY 2018-2026 (THOUSAND UNITS)
TABLE 15 NORTH AMERICA CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 ($ MILLION)
TABLE 16 NORTH AMERICA CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 (THOUSAND UNITS)
TABLE 17 EUROPE CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 ($ MILLION)
TABLE 18 EUROPE CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 (THOUSAND UNITS)
TABLE 19 ASIA PACIFIC CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 ($ MILLION)
TABLE 20 ASIA PACIFIC CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 (THOUSAND UNITS)
TABLE 21 REST OF WORLD CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 ($ MILLION)
TABLE 22 REST OF WORLD CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 (THOUSAND UNITS)
FIGURE LIST
FIGURE 1 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 2 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 (THOUSAND UNITS)
FIGURE 3 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET IN AUTOMATED INSTRUMENTS 2018-2026 ($ MILLION)
FIGURE 4 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET IN AUTOMATED INSTRUMENTS 2018-2026 (THOUSAND UNITS)
FIGURE 5 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET IN CONSUMABLES 2018-2026 ($ MILLION)
FIGURE 6 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET IN CONSUMABLES 2018-2026 (THOUSAND UNITS)
FIGURE 7 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET IN EXTRACTION/ISOLATION KITS 2018-2026 ($ MILLION)
FIGURE 8 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET IN EXTRACTION/ISOLATION KITS 2018-2026 (THOUSAND UNITS)
FIGURE 9 GLOBAL EXTRACTION/ISOLATION KITS MARKET IN MAGNETIC BEAD BASED 2018-2026 (THOUSAND UNITS)
FIGURE 10 GLOBAL EXTRACTION/ISOLATION KITS MARKET IN MAGNETIC BEAD BASED 2018-2026 ($ MILLION)
FIGURE 11 GLOBAL EXTRACTION/ISOLATION KITS MARKET IN COLUMN BASED 2018-2026 (THOUSAND UNITS)
FIGURE 12 GLOBAL EXTRACTION/ISOLATION KITS MARKET IN COLUMN BASED 2018-2026 ($ MILLION)
FIGURE 13 GLOBAL EXTRACTION/ISOLATION KITS MARKET IN OTHER EXTRACTION/ISOLATION KITS 2018-2026 (THOUSAND UNITS)
FIGURE 14 GLOBAL EXTRACTION/ISOLATION KITS MARKET IN OTHER EXTRACTION/ISOLATION KITS 2018-2026 ($ MILLION)
FIGURE 15 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET IN NGS 2018-2026 ($ MILLION)
FIGURE 16 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET IN NGS 2018-2026 (THOUSAND UNITS)
FIGURE 17 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET IN RPCR AND MULTIPLEXED PCR 2018-2026 ($ MILLION)
FIGURE 18 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET IN RPCR AND MULTIPLEXED PCR 2018-2026 (THOUSAND UNITS)
FIGURE 19 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET IN QPCR 2018-2026 ($ MILLION)
FIGURE 20 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET IN QPCR 2018-2026 (THOUSAND UNITS)
FIGURE 21 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET IN DPCR 2018-2026 ($ MILLION)
FIGURE 22 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET IN DPCR 2018-2026 (THOUSAND UNITS)
FIGURE 23 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET IN OTHER PLATFORM 2018-2026 ($ MILLION)
FIGURE 24 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET IN OTHER PLATFORM 2018-2026 (THOUSAND UNITS)
FIGURE 25 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET IN ONCOLOGY 2018-2026 ($ MILLION)
FIGURE 26 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET IN ONCOLOGY 2018-2026 (THOUSAND UNITS)
FIGURE 27 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET IN NIPT 2018-2026 ($ MILLION)
FIGURE 28 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET IN NIPT 2018-2026 (THOUSAND UNITS)
FIGURE 29 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET IN OTHER DISEASE CONDITIONS 2018-2026 ($ MILLION)
FIGURE 30 GLOBAL CELL-FREE DNA (CFDNA) TESTING MARKET IN OTHER DISEASE CONDITIONS 2018-2026 (THOUSAND UNITS)
FIGURE 31 THE UNITED STATES CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 32 THE UNITED STATES CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 (THOUSAND UNITS)
FIGURE 33 CANADA CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 34 CANADA CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 (THOUSAND UNITS)
FIGURE 35 THE UNITED KINGDOM CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 36 THE UNITED KINGDOM CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 (THOUSAND UNITS)
FIGURE 37 GERMANY CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 38 GERMANY CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 (THOUSAND UNITS)
FIGURE 39 FRANCE CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 40 FRANCE CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 (THOUSAND UNITS)
FIGURE 41 ITALY CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 42 ITALY CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 (THOUSAND UNITS)
FIGURE 43 SPAIN CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 44 SPAIN CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 (THOUSAND UNITS)
FIGURE 45 RUSSIA CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 46 RUSSIA CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 (THOUSAND UNITS)
FIGURE 47 REST OF EUROPE CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 48 REST OF EUROPE CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 (THOUSAND UNITS)
FIGURE 49 CHINA CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 50 CHINA CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 (THOUSAND UNITS)
FIGURE 51 JAPAN CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 52 JAPAN CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 (THOUSAND UNITS)
FIGURE 53 AUSTRALIA CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 54 AUSTRALIA CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 (THOUSAND UNITS)
FIGURE 55 INDIA CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 56 INDIA CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 (THOUSAND UNITS)
FIGURE 57 SOUTH KOREA CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 58 SOUTH KOREA CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 (THOUSAND UNITS)
FIGURE 59 REST OF ASIA PACIFIC CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 60 REST OF ASIA PACIFIC CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 (THOUSAND UNITS)
FIGURE 61 LATIN AMERICA CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 62 LATIN AMERICA CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 (THOUSAND UNITS)
FIGURE 63 MIDDLE EAST AND AFRICA CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 ($ MILLION)
FIGURE 64 MIDDLE EAST AND AFRICA CELL-FREE DNA (CFDNA) TESTING MARKET 2018-2026 (THOUSAND UNITS)
FIGURE 65 COMPANY MARKET SHARE ANALYSIS OF CFDNA TESTING MARKET 2017 (%)
- MARKET SEGMENTATION
- MARKET BY PRODUCTS 2018-2026
- AUTOMATED INSTRUMENTS
- CONSUMABLES
- EXTRACTION/ISOLATION KITS
- MAGNETIC BEAD BASED
- COLUMN BASED
- OTHER EXTRACTION/ISOLATION KITS
- MARKET BY PLATFORM 2018-2026
- NGS
- RPCR AND MULTIPLEXED PCR
- QPCR
- DPCR
- OTHER PLATFORM
- MARKET BY APPLICATION 2018-2026
- ONCOLOGY
- NIPT
- OTHER DISEASE CONDITIONS
- MARKET BY PRODUCTS 2018-2026
- GEOGRAPHICAL ANALYSIS
- NORTH AMERICA
- THE UNITED STATES
- CANADA
- EUROPE
- THE UNITED KINGDOM
- GERMANY
- FRANCE
- ITALY
- SPAIN
- RUSSIA
- REST OF EUROPE
- ASIA PACIFIC
- CHINA
- JAPAN
- AUSTRALIA
- INDIA
- SOUTH KOREA
- REST OF ASIA PACIFIC
- REST OF WORLD
- LATIN AMERICA
- MIDDLE EAST AND AFRICA
- NORTH AMERICA
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.